Company Description
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation.
The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease.
It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome.
In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson’s disease.
It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson’s disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan.
The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021.
Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
| Country | United States |
| Founded | 2015 |
| IPO Date | Dec 3, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Christer Rosen |
Contact Details
Address: 1001 North US Highway 1, Suite 504 Jupiter, Florida 33477 United States | |
| Phone | 561 406 6154 |
| Website | jupiterneurosciences.com |
Stock Details
| Ticker Symbol | JUNS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001679628 |
| ISIN Number | US48208B2034 |
| Employer ID | 47-4828381 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christer Rosen | Co-Founder, Chief Executive Officer and Chairman of the Board |
| Alison D. Silva MA, MS | President, Chief Business Officer and Director |
| Dr. Marshall Hayward Ph.D. | Co-Founder, Chief Scientific Officer and Director |
| Alexander Rosen | Co-Founder and Chief Administrative Officer |
| Dr. Claes Wahlestedt M.D., Ph.D. | Co-Founder, Co-Chairman of Scientific Advisory Board and Consulting Chief Medical Officer |
| Dr. Shaun P. Brothers Ph.D. | Co-Founder Member of Scientific Advisory Board and Consulting Vice President of Science Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 20, 2025 | 8-K/A | [Amend] Current report |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 6, 2025 | ARS | Filing |
| Nov 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 6, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 28, 2025 | PRER14A | Filing |
| Oct 27, 2025 | 8-K | Current Report |
| Oct 17, 2025 | PRE 14A | Other preliminary proxy statements |